A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 in Healthy Male Subjects With Increased Elevated LDL-C Levels.

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 3, 2018

Primary Completion Date

December 19, 2020

Study Completion Date

December 19, 2020

Conditions

Hypercholesterolemia

Interventions

DRUG

AZD8233

Randomized subjects will receive single SC dose of AZD8233 (dose 1, dose 2, dose 3, dose 4 and dose 5) injection.

Trial Locations (1)

Research Site, Glendale